Core Viewpoint - Ruipai Pet is set to become the "first stock in China's pet medical industry" as it submits its IPO application to the Hong Kong Stock Exchange, following the failed IPO attempt of its competitor, New Ruipeng, which withdrew its application in 2024 due to ongoing operational challenges and market conditions [1][2]. Industry Overview - The domestic pet medical industry is characterized by a fragmented competitive landscape, with a chain rate of only 22% and a CR5 of 15.4% in 2024, indicating low market concentration [1][2]. - The market for chain pet medical services is projected to grow from 11 billion yuan in 2024 to 22.6 billion yuan by 2030, with a CAGR of approximately 12.6%, and is expected to double to 49.4 billion yuan by 2035, with a slightly accelerated CAGR of 17% [1]. Company Performance - Ruipai Pet's financial performance is stronger than that of New Ruipeng, which reported a cumulative net loss of 4 billion yuan from 2019 to 2022. In contrast, Ruipai Pet achieved profitability in most years from 2022 to the first half of 2025, with adjusted net profit margins ranging from 3.9% to 7.7% [2][3]. - The company's gross margin is reported to be between 21% and 25%, with its core diagnostic services accounting for over 90% of revenue but only achieving a maximum gross margin of 22.7% [3]. Business Model Differences - Ruipai Pet employs a VDP model for acquisitions, retaining 40% of the original team's equity, which helps maintain operational stability and reduces talent loss, unlike New Ruipeng's aggressive full acquisition strategy [5][6]. - The operational efficiency of Ruipai Pet is enhanced by a three-tier medical collaboration system, which allows for better resource allocation and service quality control, contrasting with New Ruipeng's less efficient operational model [6][7]. Challenges and Risks - Ruipai Pet faces potential goodwill risks due to its acquisition strategy, with goodwill accounting for 68.4% of non-current assets and 51% of total assets as of the first half of 2025 [9]. - The overall profitability of the pet medical industry remains weak, with leading companies either operating at a loss or with thin margins, indicating a low ceiling for growth in the sector [10].

Investment Rating - The report gives a "Buy" rating for the company [5] Core Viewpoints - The company, Xiaocaiyuan, is a rapidly growing mass-market Chinese dining enterprise focusing on new Huizhou cuisine, with a core philosophy of "delicious and affordable" [5][14] - The Chinese dining market shows strong resilience, with a compound annual growth rate (CAGR) of 4.4% from 2018 to 2023, expected to reach 8.26 trillion yuan by 2028 [5][34] - Xiaocaiyuan has a significant competitive advantage in the mass-market dining segment, holding a 0.2% market share in the 50-100 yuan price range, ranking first in this category [5][40] Company Overview - Xiaocaiyuan has expanded rapidly since opening its first store in Tongling, Anhui in 2013, reaching 673 stores across 14 provinces and 146 cities by the end of 2024, with plans to exceed 800 stores in 2025 [5][14] - The company operates under a direct chain model, ensuring consistent quality and service across its outlets [29] Market Analysis - The mass-market Chinese dining segment, defined as having an average spend of under 100 yuan, accounted for 36.18 billion yuan in 2023, representing 88.7% of the overall Chinese dining market [34][36] - The segment has shown resilience with a CAGR of 3.8% from 2018 to 2023, despite challenges such as the pandemic [36] Competitive Strengths - Xiaocaiyuan's strengths include precise brand positioning, a standardized operational system, strong supply chain integration, and a robust employee incentive mechanism [4][5] - The company has established a centralized kitchen and logistics team, which has helped reduce raw material costs to 29.5% of revenue in the first half of 2025 [4] Financial Performance - Xiaocaiyuan's revenue grew from 2.646 billion yuan in 2021 to 5.21 billion yuan in 2024, with a CAGR of 25.3%, while net profit increased from 227 million yuan to 581 million yuan during the same period, with a CAGR of 36.7% [5][8] - The company maintains a gross margin above 65%, with a net margin of approximately 11% [5] Profit Forecast - The company is expected to achieve net profits of 753 million yuan, 921 million yuan, and 1.122 billion yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 29.6%, 22.4%, and 21.9% [5][8]